Bologna Pharma Development Inc. develops targeted therapeutic agents for endometriosis and breast cancer, with a focus on directing anti-hormonal treatment to disease tissue while limiting systemic exposure. Its patented technology uses vaginal delivery to concentrate aromatase inhibitors in the pelvic cavity, alongside research into local estrogen production and endoxifen-based approaches for breast cancer prevention and treatment. The company is based in New York, NY.